AT284691T - agonists and compositions of a 5HT1B / 1D a selective COX-2 inhibitor for the treatment of migraine - Google Patents

agonists and compositions of a 5HT1B / 1D a selective COX-2 inhibitor for the treatment of migraine

Info

Publication number
AT284691T
AT284691T AT99960171T AT99960171T AT284691T AT 284691 T AT284691 T AT 284691T AT 99960171 T AT99960171 T AT 99960171T AT 99960171 T AT99960171 T AT 99960171T AT 284691 T AT284691 T AT 284691T
Authority
AT
Austria
Prior art keywords
5ht1b
migraine
agonists
1d
inhibitor
Prior art date
Application number
AT99960171T
Other languages
German (de)
Inventor
Kremena Simitchieva
Scott A Reines
Errol Mckinney
Eric J Sandquist
Deepak K Khanna
Richard Hargreaves
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10660598P priority Critical
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Priority to PCT/US1999/025388 priority patent/WO2000025779A1/en
Publication of AT284691T publication Critical patent/AT284691T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
AT99960171T 1998-11-02 1999-10-29 agonists and compositions of a 5HT1B / 1D a selective COX-2 inhibitor for the treatment of migraine AT284691T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10660598P true 1998-11-02 1998-11-02
PCT/US1999/025388 WO2000025779A1 (en) 1998-11-02 1999-10-29 Method of treating migraines and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AT284691T true AT284691T (en) 2005-01-15

Family

ID=22312313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960171T AT284691T (en) 1998-11-02 1999-10-29 agonists and compositions of a 5HT1B / 1D a selective COX-2 inhibitor for the treatment of migraine

Country Status (9)

Country Link
US (3) US6384034B2 (en)
EP (1) EP1126841B1 (en)
JP (1) JP2002528498A (en)
AT (1) AT284691T (en)
AU (1) AU759307B2 (en)
CA (1) CA2348979A1 (en)
DE (1) DE69922688T2 (en)
ES (1) ES2234324T3 (en)
WO (1) WO2000025779A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
AU759307B2 (en) * 1998-11-02 2003-04-10 Merck Sharp & Dohme Corp. Method of treating migraines and pharmaceutical compositions
WO2000048583A2 (en) * 1999-02-19 2000-08-24 Pozen Inc. Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
CO5190664A1 (en) 1999-06-30 2002-08-29 Pfizer Prod Inc Combination therapy for the treatment of migraine administration of a 5HT receptor, caffeine and a cyclooxygenase-2
CN1376146B (en) * 1999-12-08 2011-04-06 法马西亚公司 Solid-state form of celecoxil having enhanced bioavailability
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
WO2001091856A2 (en) * 2000-06-01 2001-12-06 Pharmacia Corporation Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
AU8533401A (en) * 2000-08-29 2002-03-13 Peter Van Patten Prophylactic treatment of migraine
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
SK14762003A3 (en) * 2001-05-31 2004-08-03 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase- 2 inhibitor a monohydric alcohol
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
DE10129320A1 (en) 2001-06-19 2003-04-10 Norbert Mueller Use of cyclooxygenase-2 inhibitor in the preparation of a medicament for treating psychiatric disorders e.g. schizophrenia
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050106122A1 (en) * 2002-02-25 2005-05-19 Sveinbjorn Gizurarson Absorption enhancing agent
US20030224006A1 (en) * 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2004000284A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituted Pyrazolyprimidine
WO2004026235A2 (en) * 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
PT1575566E (en) 2002-12-26 2012-03-29 Pozen Inc Multilayer dosage forms containing naproxen and triptans
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
US20060171945A1 (en) * 2003-02-14 2006-08-03 Critchley Hilary Octavia D Ip receptor antagonists for the treatment of pathological uterine conditions
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
EP1644004A4 (en) * 2003-06-20 2010-10-06 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US7312236B2 (en) * 2003-12-17 2007-12-25 Eli Lilly And Company Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-HT1F agonists
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
US20070105927A1 (en) * 2005-10-20 2007-05-10 Glenmark Pharmaceuticals Limited Amorphous rizatriptan benzoate
US20080270221A1 (en) * 2006-12-18 2008-10-30 Silvaris Corporation Determining and presenting product market prices
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP2217602B1 (en) * 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
HUE027771T2 (en) 2008-04-02 2016-10-28 Boehringer Ingelheim Int 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
CA2757231A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
WO2009152551A1 (en) * 2008-06-20 2009-12-23 Alphapharm Pty Ltd Pharmaceutical formulation
EP2296652B1 (en) 2008-06-30 2017-11-08 Afgin Pharma, Llc Topical regional neuro-affective therapy
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
TWI457331B (en) 2009-02-27 2014-10-21 Helsinn Therapeutics Us Inc Enhanced migraine treatments based on ghrelin mimetics
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
AR077859A1 (en) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compounds for the treatment of disorders of the CNS
BR112013003097A2 (en) 2010-08-12 2016-06-28 Boehringer Ingelheim Int 6-Cycloalkyl pyrazolopyrimidemones for the treatment of cns disorder
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20160256410A1 (en) 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
US20180280308A1 (en) * 2017-01-04 2018-10-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
AU2018205790A1 (en) 2017-01-04 2019-07-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (en) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives, method of producing same, their use and pharmaceutical compositons on their base
RO114326B1 (en) * 1992-06-05 1999-03-30 Merck Sharp & Dohme Limited Ho Sulphate salt of a substituted triazole, process for producing the same, pharmaceutical composition and process for producing such composition
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AT212985T (en) * 1993-11-30 2002-02-15 Searle & Co benzenesulfonamide tricyclic, substituted pyrazolyl and their use as cyclooxygenase II inhibitors
JP2636819B2 (en) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 Heterocyclic aromatic oxazole compound
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
ZA9605837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
DE19542281C2 (en) 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Use of epinastine for the treatment of migraine
BR9708574A (en) * 1996-04-12 1999-08-03 Searle & Co Derivatives substituted benzenesulfonamide as COX-2 inhibitor prodrugs
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
CO4960662A1 (en) * 1997-08-28 2000-09-25 Novartis Ag Certain acids 5-alkyl-2-arylaminophenylacetic and its derivatives
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
WO1999059583A1 (en) * 1998-05-18 1999-11-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
AU759307B2 (en) * 1998-11-02 2003-04-10 Merck Sharp & Dohme Corp. Method of treating migraines and pharmaceutical compositions
WO2000048583A2 (en) 1999-02-19 2000-08-24 Pozen Inc. Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
CA2364127A1 (en) * 1999-03-01 2000-09-08 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
AU3253800A (en) * 1999-05-14 2000-11-16 Pfizer Products Inc. Combination therapy for the treatment of migraine
IL136025D0 (en) 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
IL136023D0 (en) 1999-05-14 2001-05-20 Pfizer Prod Inc 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine

Also Published As

Publication number Publication date
EP1126841A1 (en) 2001-08-29
US20020177617A1 (en) 2002-11-28
ES2234324T3 (en) 2005-06-16
DE69922688D1 (en) 2005-01-20
US20060194855A1 (en) 2006-08-31
JP2002528498A (en) 2002-09-03
AU759307B2 (en) 2003-04-10
WO2000025779A1 (en) 2000-05-11
CA2348979A1 (en) 2000-05-11
US20020016348A1 (en) 2002-02-07
EP1126841B1 (en) 2004-12-15
US6384034B2 (en) 2002-05-07
EP1126841A4 (en) 2002-06-12
AU1709800A (en) 2000-05-22
DE69922688T2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
DE69913520D1 (en) Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
DE69900362D1 (en) Composition for treating keratin fibers
DE69918087D1 (en) Topical formulations for treatment of nail fungal diseases
DE69925306D1 (en) Treatment of hydrocarbon gas
DE60019195D1 (en) Treatment by ablation of bone metastases
DE69925276D1 (en) Substances and compositions for the administration of active substances
AT311187T (en) (2-imidazolin-2-ylamino) quinoxaline for the treatment of neural injury
DE60108080D1 (en) Aminopyrazole health disorders for treatment of overweight and other
DE69521994T2 (en) Compositions containing DNA damaging agents and p53
DE69924750D1 (en) Device for thermal treatment of tissue
DE69910216D1 (en) Conjugates for treatment of inflammatory diseases and tissue damage assozierter
DE69904320T2 (en) On-chip circuitry and method for memory-circuit-test
DE69524682D1 (en) Agents for the treatment of wounds
NO20012916L (en) Compositions and methods for treating anorectal disorders
MA24837A1 (en) Disinfectant compositions and processes to disinfect surfaces
AT267595T (en) Compositions for the treatment of obesity, which are antagonists of the CB1 receptors and contain sibutramine
AT253977T (en) Device for the treatment of particulate well
AT260677T (en) Compositions and methods agents altering the biodistribution of biological
AT306481T (en) Pyrazolecarboxamide diseases for treatment of obesity and other
DE69927971D1 (en) Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis c
DE69831567D1 (en) Device for treatment of herzarrhythien
BR1100403A (en) The compound and pharmaceutical composition of Cox-2 inhibitors
DE60109164D1 (en) Methods and compositions for the treatment of pain of the mucosa
NO313939B1 (en) Heterocyclic thioesters and ketones, pharmaceutical compositions comprising the same, method of preparation and use of such compounds
DE69330138T2 (en) Methods and compositions for treating metal surfaces

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties